Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON-IDA/NEPHRO trials

American Journal of Hematology

Volumn 96, Issue 1, 2021, Pages E11-E15

  Wolf, Myles ^a   Auerbach, Michael ^b   Kalra, Philip A ^c   Glaspy, John ^d   Thomsen, Lars L ^e   Bhandari, Sunil ^f  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Pharmacosmos AS   (Denmark)

^f HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IRON ISOMALTOSE; IRON SACCHARATE;

ATRIAL FIBRILLATION; ATTRIBUTABLE RISK; CARDIOVASCULAR DISEASE; COMPARATIVE EFFECTIVENESS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; HUMAN; HYPERTENSION; INCIDENCE; IRON DEFICIENCY ANEMIA; LETTER; MAJOR CLINICAL STUDY; NAUSEA; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SINGLE DRUG DOSE; BLOOD; CLINICAL TRIAL; FEMALE; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ANEMIA, IRON-DEFICIENCY; FEMALE; FERRIC OXIDE, SACCHARATED; HUMANS; MALE;

EID: 85093982052     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.26015     Document Type: Letter

References (6)

1. Le CH. The prevalence of anemia and moderate-severe anemia in the US population (NHANES 2003-2012). PLoS One. 2016;11:e0166635.
2. Auerbach M, Henry D, Derman RJ, Achebe MM, Thomsen LL, Glaspy J. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol. 2019;94:1007-1014.
3. Bhandari S, Kalra PA, Berkowitz M, Belo D, Thomsen LL, Wolf M. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol Dial Transplant. 2020;gfaa011. https://doi.org/10.1093/ndt/gfaa011. Epub ahead of print.
4. Wolf M, Rubin J, Achebe M, et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: Two randomized clinical trials. JAMA. 2020;323:432-443.
5. Pollock RF, Biggar P. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Expert Rev Hematol. 2020;13:187-195.
6. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-12305.